Nonetheless, studies on the regulation of SOX-2 expression revealed that a neddylation inhibitor, MLN4924, can be used to target SOX-2 for anti-cancer therapy, which represses transcription of SOX-2. The gene discussed is SOX2; the disease is cancer.